United Therapeutics (UTHR) Gains from Investment Securities (2009 - 2026)

United Therapeutics has disclosed Gains from Investment Securities across 18 years of filings, most recently posting $58.3 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $58.3 million, up 1521.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $82.1 million (down 78.73% YoY), and the FY2025 annual result was $19.7 million, down 95.08% from the prior year.
• Gains from Investment Securities came in at $58.3 million for Q1 2026 at United Therapeutics, up from $33.6 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $273.3 million in Q3 2024 to a low of -$241.6 million in Q4 2022.
• The 5-year median for Gains from Investment Securities is $5.5 million (2024), against an average of $1.5 million.
• Across the five-year window, Gains from Investment Securities surged 3275.0% in 2023 and sank 280.0% in 2025, its largest moves.
• United Therapeutics' Gains from Investment Securities stood at -$241.6 million in 2022, then gained by 4.39% to -$231.0 million in 2023, then surged by 148.18% to $111.3 million in 2024, then tumbled by 69.81% to $33.6 million in 2025, then surged by 73.51% to $58.3 million in 2026.
• The last three Gains from Investment Securities figures came in at $58.3 million (Q1 2026), $33.6 million (Q4 2025), and $100000.0 (Q3 2025), per Business Quant data.